Repertoire Immune Medicines secures $189M

By The Science Advisory Board staff writers

April 13, 2021 -- Repertoire Immune Medicines has completed a round of financing, raising $189 million to further expand its Decode discovery platform, accelerate its clinical and preclinical pipeline, expand its team, and enhance its manufacturing capabilities.

The Decode platform aims at decoding the interactions between T cells and antigens to create new classes of immune medicines for cancer, immune disorders, infectious diseases, and other conditions. The platform allows for in-depth characterization of T cell receptor-antigen pairs, and the ability to rationally design and develop novel targeted immune medicines, according to the company.

The funding will also support the advancement of multiple clinical programs in immuno-oncology using Repertoire's proprietary antigen-primed multiclonal cytokine-enhanced T-cell products in solid tumors. The company's Prime interleukin-15 (IL-15) program in advanced metastatic solid tumors is ongoing, and a data readout is expected later this year.

Meanwhile, the company anticipates initiating a clinical program for its Prime IL-12 program in human papillomavirus (HPV)-16+ solid tumors by mid-year.

The company was founded by Flagship Pioneering and has since raised more than $350 million since its launch in December 2019.

Tessera closes $230M in series B round for gene writing tech
Tessera Therapeutics has raised over $230 million in series B financing to advance its gene writing technology, capable of writing therapeutic instructions...
New AI-based company targets discovery of new protein-based therapeutics
Flagship Pioneering has launched Generate Biomedicines, a new company that will use its machine learning-powered platform for the rapid discovery of new...
Tessera introduces new genome engineering strategy
Flagship Pioneering, a life science venture capital firm, has introduced Tessera Therapeutics -- a new biotechnology company that will use its Gene Writing...

Copyright © 2021

Building Biology in 3D Hybrid Symposium
October 26-27
La Jolla, California United States
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter